All News

In a phase 2a trial, the oral NLRP3 inhibitor VTX3232 significantly reduced systemic and liver inflammation markers—including hsCRP and IL-6—independent of weight loss, suggesting a promising new approach to lowering cardiovascular risk in patients with obesity.

A phase 3 trial found that the oral PCSK9 inhibitor enlicitide significantly outperformed existing oral therapies in lowering LDL cholesterol.

New research identifies caspase-8 loss as a key driver of inflammatory reprogramming and tumor recurrence in small cell lung cancer.

Kelly Gable, PharmD, shares how empathy, presence, and practical guidance can transform patient experiences beyond the medication plan.

Learn how NABP’s FPGEC verifies foreign pharmacists and why TOEFL English proficiency standards remain central to US patient safety.

Alex Wolff, PharmD, BCOP, FHOPA, explains how patient populations, delivery models, and safety risks shape real-world implementation.

Evolocumab produced a 31% relative risk reduction in major cardiovascular events.

From a pipeline exploding with oral and injectable options to emerging evidence in liver disease, substance use disorder, and kidney disease, Emily Eddy, PharmD, laid out the full scope of incretin therapy's expanding reach at APhA 2026.

SCOUT-HCM trial showed that mavacamten reduced left ventricular outflow tract obstruction in adolescents with obstructive HCM.

The trial's success offers the first robust evidence for targeted pharmacologic intervention in adolescent oHCM.

The CADENCE trial showed that sotatercept reduced pulmonary vascular resistance and improved right ventricular function in CPC-PH.

Finerenone consistently reduces heart failure events and cardiovascular death regardless of ischemic heart disease history, according to the FINEARTS-HF trial.

The KARDINAL trial demonstrated meaningful angiotensinogen reduction with a novel monthly injectable therapy.

For decades, the medical community has operated under a reactive model for the most potent cholesterol-lowering drugs, largely reserving them for secondary prevention.

At APhA 2026, Damika Walker, PharmD, RPh, argued that closing stubbornly low adult vaccination rates requires a shift in how pharmacists approach every patient encounter.

The findings emphasize that when it comes to the complex machinery of human blood pressure, more drug is not always better.

With updated recommendations for adults aged 50 and older, pharmacy teams are uniquely positioned to bridge gaps in care through community engagement and proactive clinical assessments.

The 2026 guidelines bring clinically meaningful updates to specific LDL-C targets, risk calculation, earlier intervention strategies, and expanded use of ApoB.

Gene and cell therapies are reshaping clinical workflows—and pharmacists are becoming essential guides in that shift.

Pharmacists and clinicians share strategies to streamline training, collaboration, and patient care with BTCEs.

A community-based initiative is proving that the path to heart health for Black men may not start in a physician’s office, but in the barber’s chair.

Disease burden, monitoring strategy, and timing of therapy drive CRS risk and management.

Historically, dulaglutide was a preferred choice because it was proven to reduce major adverse cardiovascular events in the REWIND trial.

Ivermectin, fenbendazole, and mebendazole have gained traction as alternative cancer therapies despite a lack of clinical evidence.

The RECOVER-AUTONOMIC trial underscores the necessity of better clinical end points to assess interventions in the long COVID population.